Tumor-targeting CTL expressing a single-chain Fv specific for VEGFR2

• Published in: Biochemical and biophysical research communications Vol. 394; no. 1; pp. 54 - 58
• Main Authors: Kanagawa, Naoko, Yanagawa, Tatsuya, Mukai, Yohei, Yoshioka, Yasuo, Okada, Naoki, Nakagawa, Shinsaku
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 26.03.2010
• Subjects: Adoptive immunotherapy; Animals; Cell Line, Tumor; Cytotoxic T lymphocyte; Genetic Engineering; Immunotherapy, Adoptive - methods; Mice; Mice, Inbred C57BL; Neoplasms - immunology; Neoplasms - therapy; scFv; Single-Chain Antibodies - biosynthesis; Single-Chain Antibodies - genetics; T-Lymphocytes, Cytotoxic - immunology; T-Lymphocytes, Cytotoxic - transplantation; Targeting; Vascular Endothelial Growth Factor Receptor-2 - antagonists & inhibitors; Vascular Endothelial Growth Factor Receptor-2 - immunology; VEGFR2; VEGFR2; PBS; TCR; IL; Targeting; VEGF; Adoptive immunotherapy; gp; mAb; VH; scFv; FBS; VL; scFv-CTL; CTL; OVA; Cytotoxic T lymphocyte
• ISSN: 0006-291X; 1090-2104
• DOI: 10.1016/j.bbrc.2010.02.085

Cytotoxic T lymphocytes (CTL) are critical effector cells in tumor immunity. Adoptive transfer therapy with in vitro-expanded tumor-specific CTL is a promising approach for preventing cancer metastasis and recurrence. Transferred CTL are not effective in clinical trials, however, due to inadequate tumor-infiltration. Therefore, the development of functionally modified CTL, such as tumor-targeting CTL, is widely desired. Here, we designed the tumor-targeting CTL expressing a single-chain antibody fragment (scFv-CTL) specific for vascular endothelial growth factor receptor 2 (VEGFR2/flk1) by transducing the CTL with a retroviral vector. The scFv-CTL bound to VEGFR2/flk1-expressing cells and retained their cytotoxic activity against tumor cells. In addition, adoptive transfer of scFv-CTL into tumor-bearing mice effectively suppressed tumor growth due to the augmented accumulation of the transferred CTL in the tumor tissue. These findings indicate that the creation of CTL capable of targeting tumor vascular endothelial cells by scFv-expression technique is considerably promising for improvement of efficacy in adoptive immunotherapy.